Results
-Of the total of 87 participants, 20 (23%) had attempted suicide.
Patients with a history of suicide attempts had significantly higher scores on the BDI (p=0.036) and K-ISMI (p=0.009), and significantly lower scores on the SES (p=0.001). Analysis of covariance revealed that the SES scores were significantly lower in patients with a history of previous suicide attempts than in those with no history, after controlling for K-ISMI and BDI scores (p = 0.039).
Conclusion
-Low self-esteem appears to represent a psychological dimension that is closely related to suicide risk. Therefore, clinical attention should be paid to the evaluation and enhancement of low self-esteem in schizophrenia patients with suicidality. A longitudinal prospective study is required to ascertain whether low self-esteem leads suicide attempts.
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Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment Abstract Background: Second-generation antipsychotics (SGAs), such as olanzapine, are used to treat schizophrenia; however, they have minimal benefits for cognitive deficits and cause metabolic side-effects such as obesity [1, 2] . Obesity has been linked to increased cognitive impairment [3] , complicating the health issues of people with schizophrenia. Liraglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist with antiobesity and neuroprotective properties [4, 5] ; however, whether liraglutide can improve cognition during olanzapine treatment is unclear. The aim of this study was to examine the effects of liraglutide co-treatment on cognition and metabolic parameters during olanzapine treatment. Methods: Sprague-Dawley rats were administered olanzapine (2mg/kg), liraglutide (0.4mg/kg), olanzapine+liraglutide cotreatment or vehicle (control) (n=12/group) for six weeks. Body weight, food intake and locomotor activity were recorded. Novel object recognition (NOR) and T-maze tests were conducted to examine recognition and working memory. Post-mortem white adipose tissue weight was recorded. Results: Olanzapine caused significant body weight gain and increased white adipose tissue mass (p<0.05 vs control), whereas liraglutide co-treatment significantly reduced body weight and adiposity (p<0.001 vs olanzapine). Olanzapine induced hypolocomotion (p<0.001 vs control), whereas liraglutide co-treatment significantly increased locomotor activity (p<0.05 vs olanzapine). In the NOR test, olanzapine-treated rats spent significantly less time exploring the novel object, and this was significantly improved in the liraglutide co-treatment group (p<0.01 vs olanzapine). There was no effect of treatment on correct entries in the T-maze test (p>0.05 vs control). Conclusion: This study demonstrates that liraglutide co-treatment can improve locomotor activity, decrease adiposity and prevent weight gain side-effects associated with olanzapine administration. Liraglutide co-treatment was able to improve recognition memory impairment caused by olanzapine treatment; however, it had no effect on working memory. Further studies are required to understand the mechanisms underlying these changes, and to elucidate whether a link exists between olanzapine-induced obesity and liraglutide's effect on cognition.
